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During HIV infection, the timing of opportunistic infections is not always associated with severity of
CD4 T cell depletion, and different opportunistic pathogens reactivate at different CD4 T cell thresh-
olds. Here, we examine how differences in the phenotype and function of pathogen-specific CD4
T cells influence susceptibility to HIV infection. By focusing on three common opportunistic infec-
tions (Mycobacterium tuberculosis, human papillomavirus, and cytomegalovirus), we investigate
how differential depletion of pathogen-specific CD4 T cells impacts the natural history of these
pathogens in HIV infection. A broader understanding of this relationship can better inform treatment
strategies against copathogens.Introduction
Chronic, untreated HIV infection is char-
acterized by progressive depletion of
CD4 T cells, increasing the risk of coinfec-
tionwith pathogens typically controlled by
innate and adaptive immune responses.
Though the mechanisms leading to CD4
T cell depletion are complex, susceptibil-
ity to opportunistic infections has gener-
ally been associated with progressive
declines in CD4 T cell counts. However,
the timing of opportunistic infections is
not always associated with severity of
CD4depletion. Tuberculosis (TB) infection
can reactivate when CD4 T cell counts are
high, and infection with Candida species
can occur at any CD4 T cell count
(Figure 1).
Initiation of antiretroviral therapy (ART)
halts HIV replication and raises CD4 T cell
counts but does not always restore path-
ogen-specific immunity to normal levels.
For example, HIV-positive individuals on
ART with CD4 >700/mm3 have 4-fold
higher rates of TB disease than HIV unin-
fected individuals in the same community
(Gupta et al., 2012). The impact of ART
on human papillomavirus (HPV) infection
has been controversial, with some studies
demonstrating reduced HPV prevalence
and regression of HPV-associated squa-
mous intraepithelial lesions (SIL), whereas
others fail to show any impact on HPV-
associated disease.(Adler, 2010)It is thought that functional defects and
depletion of pathogen-specific CD4
T cells by HIV occur at varying rates, ac-
counting for differences in pathogenesis
of specific opportunistic infections (Geld-
macher and Koup, 2012). However, it re-
mains unclear whether differences in path-
ogenesis are due to differences in
pathogen-specificCD4Tcell susceptibility
to HIV infection or other factors. Here, we
examine the immunopathogenesis of three
infections causing substantial morbidity
and mortality in HIV-infected individuals:
TB, HPV, and cytomegalovirus (CMV). We
propose that understanding the complex
interplay between HIV and these patho-
gens will provide insight into differences
in disease prevalence and impact of ART
on the natural history of infection.
HIV-TB
Epidemiology and Burden
of Disease
HIV and TB coinfection remains a serious
global health problem. According to the
World Health Organization, there were
8.7million new cases of TB and 1.4 million
deaths due to TB disease in 2011 (World
Health Organization, 2012). TB is a lead-
ing cause of death amongHIV-infected in-
dividuals, especially in Africa, where
>50% of deaths in persons with HIV are
due to TB disease (Bates et al., 2013).
HIV is a leading risk factor for TB disease,Cell 155with rates of active TB doubling within 1
year of HIV seroconversion and
increasing >4-fold in chronic HIV infection
(Lodi et al., 2013; Sonnenberg et al.,
2005). Although ART reduces the inci-
dence of TB disease, rates of TB in indi-
viduals with reconstituted immune sys-
tems remain higher than in the general
population (Gupta et al., 2012). This sug-
gests that HIV infection induces functional
defects in the immune response to TB that
persist despite immune reconstitution.
Cell-Mediated Immune Response
to TB
Interactions between the host’s innate
and adaptive immune system and the or-
ganism dictate the outcome of infection
with Mycobacterium tuberculosis (Mtb).
Although innate immune cells are an
important component of the immune
response to TB infection (van Crevel
et al., 2003), it is clear that T cells are
essential for containing Mtb. Mice defi-
cient in CD4 T cells have reduced survival
and greater bacterial burden following
aerosol exposure to Mtb than do their
wild-type counterparts (Caruso et al.,
1999). Antibody-mediated depletion of
CD4 T cells in mice results in rapid reacti-
vation of persistent TB infection and
reduced survival (Mogues et al., 2001).
Similarly, nonhuman primates (NHP)
depleted of CD4 T cells have an increased
incidence of active TB disease following, October 24, 2013 ª2013 Elsevier Inc. 505
Figure 1. Incidence of Select Opportunistic Infections Stratified by CD4 Count
Data are adapted from several cohort studies of HIV-positive individuals (Anglaret et al., 2012; Minga et al.,
2008; Mocroft et al., 1998, 2013; Mun˜oz et al., 1993; Yazdanpanah et al., 2001). The bar color indicates the
approximate incidence rate (IR) per 100 person-years for each respective opportunistic pathogen. Dark
orange represents IR >10; orange = IR between 5 and 10; light orange = IR between 1 and 5; white = IR <1.
As CD4 counts increase, differences in the incidence rates of opportunistic infections emerge. The inci-
dence of CMV EOD is rare when CD4 counts are >200, whereas the incidence of esophageal candidiasis
remains moderately elevated at CD4 counts between 200 and 350, and cases of pulmonary tuberculosis
continue to occur at CD4 counts >500.Mtb exposure and a higher rate of reacti-
vation TB compared to non-CD4-
depleted monkeys (Lin et al., 2012). SIV
infection of NHP with latent TB infection
results in reactivation of TB in all infected
monkeys, albeit at different rates (Die-
drich et al., 2010). Monkeys reactivating
earlier exhibited a greater initial decline
in CD4/8 T cells following SIV infection
and had fewer CD4 T cells within their air-
ways. Taken together, these animal
studies support the critical role that CD4
T cells play in controlling TB infection.
Why are CD4 T cells important? For
one, they are a major source of IFNg,
which is necessary for the production of
reactive nitrogen intermediates and for
the killing of intracellular mycobacteria
bymacrophages. In fact, IFNg specifically
from CD4 T cells is required for a robust
CD8 T cell response and for inhibiting
intracellular replication of tubercle bacilli
within macrophages (Green et al., 2013).
The critical role of IFNg in controlling
Mtb is best demonstrated in mice devoid
of IFNg or with impaired IFNg signaling,506 Cell 155, October 24, 2013 ª2013 Elseviwhich rapidly succumb to TB disease
(Flynn et al., 1993; Kamijo et al., 1993).
In the same vein, humans with mutations
in genes encoding IFNg receptor 1 or
with polymorphisms in the IFNg gene are
at increased risk ofmycobacterial disease
(Lo´pez-Maderuelo et al., 2003; Newport
et al., 1996). CD4 T cells are also crucial
in maintaining the integrity and architec-
ture of granulomas in TB infection (Heuts
et al., 2013; Saunders et al., 2002).
Expression of CXCR5, a chemokine re-
ceptor that is important in B and T cell
homing to lymphoid tissue, appears to
be an important mediator of CD4 T cell
localization within granulomas, facilitating
lymphoid follicle formation and better pro-
tective outcomes (Slight et al., 2013).
Studies of chronic viral infections in an-
imals and humans suggest that, with viral
control, the ability of CD4/8 T cells to pro-
duce multiple cytokines (polyfunctional
T cells) increases (Harari et al., 2005; Pan-
taleo and Harari, 2006). Whether this
paradigm holds true for TB infection re-
mains debatable. TB vaccine studies iner Inc.animals have equated increased fre-
quencies of polyfunctional T cells to pro-
tection from aerosol Mtb challenge
(Aagaard et al., 2009; Forbes et al.,
2008). Polyfunctional T cells are induced
in humans following the administration of
novel TB vaccine formulations (Abel
et al., 2010; Scriba et al., 2012), but
whether this results in enhanced protec-
tion remains to be seen. Individuals with
smear-positive TB disease or untreated
TB disease have reduced frequencies of
polyfunctionalCD4Tcells compared to in-
dividuals with smear-negative TB disease
or with latent or treated TB infection (Day
et al., 2011; Harari et al., 2011). These
data suggest that, as mycobacterial
burden is reduced or controlled, T cell re-
sponses are characterized by the ability
to produce multiple cytokines. However,
not all authors have reached similar
conclusions (Caccamo et al., 2010; Su-
therland et al., 2009). It is possible that
differences in methodology or patient
populations may account for the discor-
dant results.
Impact of HIV Infection
on M. tuberculosis Cell-Mediated
Immunity
HIV coinfection adversely affects T cell re-
sponses to Mtb. Peripheral T cells
from HIV-TB-coinfected individuals have
impaired proliferation and have reduced
IFNg production in response to Mtb anti-
gen stimulation compared to TB monoin-
fected patients.(Geldmacher et al., 2008;
Zhang et al., 1994). Similar defects have
been observed in Mtb-specific CD4
T cells isolated from lung lavage samples
of HIV-infected individuals (Bonecini-Al-
meida et al., 1998; Kalsdorf et al., 2009).
In addition, HIV coinfection alters the
quality of the T cell response, resulting in
reduced frequencies of polyfunctional
T cells (Day et al., 2008; Jambo et al.,
2011; Kalsdorf et al., 2009).
How soon after HIV infection are impair-
ments in T cell responses seen? Dramatic
decreases in Mtb-specific memory CD4
T cells (CD27+CD45RO+) were observed
within 1 year of HIV seroconversion in
four out of five individuals with latent TB
infection (Geldmacher et al., 2008). The
early depletion of Mtb-specific CD4
T cells can be explained by distinct func-
tional and phenotypic characteristics of
these cells. First, Mtb-specific CD4
T cells have increased expression of the
chemokine receptor CCR5, which also
serves as a HIV coreceptor, leading to
increasedHIV entry intoCD4T cells (Geld-
macher et al., 2010). More importantly,
Mtb-specific CD4 T cells preferentially
produce IL-2 upon stimulation. IL-2 pro-
duction not only supports proliferation of
antigen-specific T cells, but also promotes
HIV replication (Geldmacher et al., 2010).
In contrast, CMV-specific CD4 T cells
tend to secrete b chemokines, such as
MIP-1b, which can reduce susceptibility
to HIV infection by hindering HIV binding
to CCR5. Lastly, most Mtb-specific CD4
T cells express CD27, a cell surface
marker associated with an early differenti-
ated phenotype and replicative potential.
CMV-specific CD4 T cells, on the other
hand, rarely expressCD27 andmore often
express CD57 (Geldmacher and Koup,
2012). Antigen-specific CD4 T cells ex-
pressing CD57 are more terminally differ-
entiated, having reduced proliferative
capacity and thus harboring lower cellular
HIV loads (Brenchley et al., 2004).
Although we believe that the early
depletion of Mtb-specific CD4 T cells
following HIV infection is an important
contributor to the increased risk of TB dis-
ease, other mechanisms increasing TB
reactivation risk in HIV-TB-coinfected in-
dividuals should not be overlooked. HIV
infection of macrophages reduces the
apoptotic response to Mtb and downre-
gulates macrophage autophagy (Patel
et al., 2009; Zhou and Spector, 2008).
This not only results in bacterial persis-
tence, but also could limit antigen presen-
tation to T cells. Observational studies
have noted a high frequency of vitamin D
deficiency among HIV-infected individ-
uals, and vitamin D deficiency has been
associated with active TB disease (Viard
et al., 2011; Wilkinson et al., 2000). The
bioactive form of vitamin D, 1,25 dihy-
droxyvitamin D3, restricts Mtb growth by
inducing the expression of cathelicidin
antimicrobial peptide, which is important
in the induction of macrophage auto-
phagy (Campbell and Spector, 2012; Liu
et al., 2006). Finding ways to manipulate
this pathway to modulate the host im-
mune response to TB is of great interest.
One additional factor contributing to
increased TB risk is the genetic diversity
of the pathogen itself. Strains of Mtb
vary in their inhibition of innate immune
responses and in virulence. A recentstudy suggests that strains of the modern
lineage induce a lower inflammatory
response, selecting for more rapid pro-
gression to active TB than strains of the
ancient lineage (Portevin et al., 2011).
Further research on the immunobiology
and clinical outcomes of various Mtb
strains is needed to more fully understand
the consequences of strain diversity in
Mtb.
Impact of ART on TB Disease
Suppression of HIV replication by ART
leads to increases in CD4 T cell count
and demonstrablemortality andmorbidity
benefits in patients coinfected with TB.
This is especially true in individuals with
CD4 counts <50 cells/mm3 if ART is
started after 2 weeks of TB treatment
(Havlir et al., 2011). ART reduces the risk
of TB disease by 67% (Lawn et al.,
2011). This may be due to increases in
naive and central memory CD4 T cell
pools along with increases in IFNg secre-
tion or polyfunctional T cell responses
following ART (Sutherland et al., 2010;
Wilkinson et al., 2009). However, despite
HIV viral load suppression and reconstitu-
tion of CD4 T cell counts, ART-treated pa-
tients continue to have risks of TB disease
that exceed that of the HIV-uninfected
population (Girardi et al., 2005). One
possible explanation for this is that ART
does not restore Mtb-specific immune re-
sponses to levels observed in HIV-unin-
fected individuals (Schluger et al., 2002;
Sutherland et al., 2006).
HIV-HPV
Epidemiology and Burden
of Disease
HPV is the most common sexually trans-
mitted infection (STI) globally. Persistent
infection with oncogenic HPV types is
linked to development of dysplastic
changes in the cervix, vulva, and anorec-
tal regions. If persistent, these dysplastic
changes can progress to invasive squa-
mous cell carcinoma.
Infection with HIV is associated with an
increased prevalence of HPV infection,
infection with multiple HPV types, and
increased incidence of cervical cancer
and other anogenital malignancies
(Luchters et al., 2010; Singh et al., 2009).
Lower CD4 T cell counts and higher HIV
viral loads are independent risk factors
for HPV infection and infection with multi-
ple HPV types (Palefsky et al., 1999).Cell 155Natural history studies demonstrate
that 70%–80% of sexually active young
women who develop incident cervical
HPV infection clear their infection within
12 to 30 months (Evander et al., 1995; Ho
et al., 1998). Young women with low-
gradecervical lesions (CIN I) showsponta-
neous regression rates ranging from 45%
to 90%, whereas women with precancer-
ous lesions (CIN III) show only an 11%
regression rate (Insinga et al., 2009).
Although factors influencing the natural
history of these different lesions are not
completely known, cell-mediated immune
responses are thought to play a role.
Cell-Mediated Immune Response
to HPV Infection
Immunohistopathological studies reveal
that, at the time of regression, HPV-in-
fected genital lesions are infiltrated with
CD8 cytotoxic T cells (CTL), CD4 T cells,
and macrophages, suggesting that a
cell-mediated immune response is inte-
gral to the control of HPV infection
(Coleman et al., 1994). Further evidence
implicating T cells in the control of HPV
infection comes from studies evaluat-
ing functional responses of T cells to
HPV early antigens. Cellular immune
responses directed against HPV16 E6
and E7 are associated with regression of
HPV16-associated cervical lesions (Kad-
ish et al., 2002; Sarkar et al., 2005).
HPV16-specific T cell responses are
more frequently detected in women with
resolved cervical HPV16 infection than
with persistent infection (Farhat et al.,
2009; Nakagawa et al., 2000). Finally,
HPV16-specific responses are largely
absent or are severely impaired in women
with cervical cancer (de Jong et al., 2004).
These data imply that control of HPV
infection requires a robust systemic
T cell response. This observation is further
supported by a recent study in which
vaccine-induced regression of HPV16
high-grade vaginal intraepithelial neo-
plasia (VIN) was more common in women
exhibiting strong and broad IFNg-asso-
ciated CD4 T cell responses to HPV 16
E6 and E7 proteins (Welters et al., 2010).
Impact of HIV Infection on HPV
Cell-Mediated Immunity
Evidence of direct biological effects of
HIV on HPV infection comes from two
studies of HPV reactivation. Strickler
et al. evaluated the rate of new HPV DNA
detection in sexually inactive (18 months, October 24, 2013 ª2013 Elsevier Inc. 507
of sexual abstinence) HIV-positive and
HIV-negative women. HPV DNA was de-
tected in 5% of sexually inactive HIV-
negative women, compared to 22% of
HIV-positive women with advanced dis-
ease (CD4 T cell count <200 cells/mm3)
(Strickler et al., 2005). Higher HPV reacti-
vation rates in HIV-infected women were
also reported by Thieler and colleagues,
who noted an association between HPV
reactivation and declining CD4 T cell
counts (Theiler et al., 2010). These studies
not only support the concept of HPV reac-
tivation, but also show that progressive
CD4 depletion increases the risk of HPV
reactivation.
If the risk of HPV infection is related to
CD4 depletion, the risk should increase
soon after HIV seroconversion. Why
would this be the case? It is well known
that, during acute HIV and SIV infection,
there is rapid depletion of memory CD4
T cells within the mucosa, including the
endocervical compartment (Mattapallil
et al., 2005; Veazey et al., 1998; Zhang
et al., 1999). If CD4 T cells are critical to
the control of HPV infection, the profound
depletion of CD4 T cells within the genital
tract soon after HIV infection should in-
crease the risk of HPV infection.
Recently, two groups evaluated the
impact of incident HIV on the detection
of HPV infection. Relative to HIV-unin-
fected women, HIV-infected women had
higher rates of HPV detection at their first
visit following HIV seroconversion (Nowak
et al., 2011; Wang et al., 2011). HIV sero-
converters had a 5-fold increased risk of
HPV infection with multiple HPV types
and a 2.5-fold increased risk of infection
with any single HPV type (Nowak et al.,
2011). Moreover, HIV seroconversion
was associated with a 2.5-fold increased
risk of low-grade cervical cytological ab-
normalities (Wang et al., 2011). These
studies provide evidence of increased
rates of HPV infection following HIV sero-
conversion, which may be driven in part
by the rapid HIV-associated CD4 T cell
depletion within the cervical mucosa.
Why would CD4 T cells in the genital
tract be subject to rapid depletion? A
recent study of cervical CD4 T cells from
female sexworkers inKenya characterized
a subset of activated cervical CD4 T cells
that produce IL-22 and IL-17a, identifying
a Th17 cell population within the cervix
(McKinnon et al., 2011). Th17 cells are508 Cell 155, October 24, 2013 ª2013 Elseviconsistently depleted from the gutmucosa
inHIV-positive individuals (Brenchleyet al.,
2008; Raffatellu et al., 2008). The authors
showed that cervical Th17 cells express
HIV susceptibility markers CCR5 and in-
tegrin a4b7. Integrin a4b7 is a lymphocyte
mucosal homing marker that also serves
as a cellular receptor for HIV-1 gp120
(Cicala et al., 2011). Although integrin
a4b7 is not required for HIV infection, it
can enhance CD4 T cell susceptibility to
HIV infection. McKinnon and colleagues
showed that coexpression of these recep-
tors by cervical CD4 T cells increased sus-
ceptibility to HIV infection and targeted
depletion (McKinnonetal., 2011).Although
the rapid depletion of cervical CD4 T cells
is driven by productive HIV infection of
these cells, increased immune activation
within genital mucosa may also contribute
to CD4 T cell loss (Jaspan et al., 2011).
Although CD4 T cell depletion within the
genital mucosa may contribute to the
increased risk of HPV infection, it remains
unclear whether HPV-specific T cells are
being preferentially targeted and depleted.
Further research assessing the effects of
HIV on the kinetics of HPV-specific T cells
within the genital mucosa is needed.
Impact of ART on HPV Infection
The impact of ART on the natural history
of HPV infection and its associated com-
plications remains uncertain. The partial
immune reconstitution observed with
ART has decreased rates of some AIDS-
defining malignancies, namely Kaposi’s
sarcoma and non-Hodgkin lymphoma;
however, the same benefits have not
been observed with respect to HPV-asso-
ciated cervical cancer (Table 1). One
theoretical explanation is that, by pro-
longing survival of HIV-infected women,
ART increases the cumulative exposure
to oncogenic HPV types, allowing for pro-
gression of HPV-related disease.
A number of clinical studies have evalu-
ated the impact of ART on HPV infection
and HPV-related cervical disease and are
reviewed in detail elsewhere (Adler, 2010).
Importantly, two large, longitudinal cohort
studies of HIV-positive women offered
conflicting data on the effects of ART on
HPV disease prevalence and HPV-related
cervical disease (Adler, 2010). However,
in a very recent publication, Blitz et al.
found that ART increases the likelihood of
cervical SIL regression (HR 3.3) while also
increasing clearance rates of oncogenicer Inc.HPV types, although this was type specific
(Blitz et al., 2013). The conflicting results
may be due to differences in primary end-
points, cohort design, or definitions of
cytological progression/regression. One
additional factor to consider is the assess-
ment of ART efficacy. Minkoff and col-
leagues showed that women who were
adherent to ART had a more significant
decline in detection of oncogenic HPV
and a more rapid clearance of HPV SIL,
compared tononadherentwomen (Minkoff
et al., 2010). Although there seems to be
mounting evidence that ART may have a
beneficial impact on the natural history of
HPV, the extent and magnitude of this ef-
fect are not clear, and the influence of
ART on the kinetics of HPV-specific immu-
nity remains largely unknown.
Impact of HPV on HIV
Sexually transmitted infections such as
herpes simplex virus 2 and syphilis have
a profound impact on HIV acquisition. A
recent review assessed the association
of HPV infection with HIV acquisition.
Women with prevalent HPV infection, irre-
spective of HPV type, had a 2-fold higher
risk of HIV infection. An increased risk of
HIV acquisition was also observed in
men with HPV infection, though this data
was generated from only two observa-
tional studies (Houlihan et al., 2012).
Biologically, it is plausible that HPV
infection could affect HIV acquisition and
dissemination. As just described, T cells
are an integral component of the host im-
mune response to HPV. Given that CD4
T cells are primary targets for HIV, a robust
T cell response to HPV infection could in-
crease risk of HIV acquisition and dissem-
ination. Langerhans cells are found in the
mucosal layer of the genital tract and are
generally refractory to HIV transmission
(deWitte et al., 2007).Depletionof Langer-
hans cells within the cervical epithelium in
HPV infection could contribute to
increased HIV acquisition (Connor et al.,
1999; Tay et al., 1987). Additionally,
E-cadherin, an epithelial adhesion mole-
cule, is downregulated during HPV infec-
tion (Matthews et al., 2003; Vessey et al.,
1995), which could potentially increase
genital mucosa permeability to HIV.
Given that HPV is themost common STI
worldwide, a more thorough understand-
ing of the contribution of HPV infection to
the HIV epidemic is required. Further
research into the biological mechanisms
Table 1. Incidence of AIDS- and Non-AIDS-Defining Malignancies in HIV-Positive Individuals and the Influence of ART
Cancer Type
Mean Standardized Incidence Ratios (Range) Incidence Rate per 100,000 Person-Years
Pre-ART Era Early ART Era Late ART Era
0–6 Months
Post-ART
6 Months–10 Years
Post-ART
AIDS-Defining Cancers
Kaposi sarcoma 1,555.5 (246–2628.5) 448.3 (47.8–848.8) 317.1 (22.9–572) 1,342 164
Non-Hodgkin’s lymphoma 537.3 (103–1011.8) 260.4 (26.7–494.4) 107.3 (16.2–212.2) 357 134
Non-Hodgkin’s lymphoma (CNS) 160 24
Cervical 69.8 (8.4–149.9) 99.2 (3.7–194.6) 88 (41.5–134.5) n/a n/a
Non-AIDS-Defining Cancers
Anal 44.5 (19–97.9) 90.1 (48.3–112.0) 78.4 (44–141.4) 72 69
Hodgkin’s lymphoma 16.5 (4.5–34.3) 28.9 (11.1–54.7) 36.4 (20.7–64.4) 144 47
Liver 9.1 (0–19.9) 17.5 (5.9–35.9) 13.7 (6.1–35.4) 18 39
Lung 24.3 (0–91.9) 33.2 (2.8–93.8) 23.5 (2.4–84.9) 54 56
Prostate 5.3 (0–14.7) 13.3 (0–38.0) 9.9 (0–37.5) 22 58
Breast 19.1 (0.6–56.0) 35.5 (1.2–69.9) 32.5 (0.6–96.0) 177 122
Head and neck 9.2 (1.4–29.0) 12.1 (2.2–31) 10.6 (1.5–36.9) n/a n/a
Melanoma 4.4 (0–15.6) 8.5 (0–24.8) 10.7 (0.6–37.5) n/a n/a
HPV-related cancers 108 103
Themean standardized incidence ratios (SIR) were calculated by averaging SIR reported in several studies of cancer risk in persons with HIV (DalMaso
et al., 2009; Franceschi et al., 2010; Patel et al., 2008; Powles et al., 2009). The pre-ART era covers the years prior to 1996, the early ART era covers
1996–2001, and the late ART era covers 2002–2007, though there is some overlap between the studies. The incidence ratios of Kaposi sarcoma (KS)
and non-Hodgkin lymphoma (NHL), both AIDS-defining cancers, decrease considerably from the pre-ART era to the late ART era. This is not seen with
cervical cancer. In a separate study, administration of ART for >6months reduced the incidence of both KS and NHL, though no difference in incidence
of HPV-related malignancies was noted (Yanik et al., 2013).underlying this increased risk should be
pursued. With the implementation of
routine HPV vaccination, studies evalu-
ating the impact of HPV vaccination on
the HIV epidemic should be considered.
HIV-CMV
Epidemiology and Burden of
Disease
CMV is a member of the human herpes-
virus family. More than half of the adult
human population is infected with CMV,
with higher rates of infection in HIV-posi-
tive individuals (Bate et al., 2010; Lang
et al., 1989). Following primary infection,
the virus is not eliminated but remains in
a latent state within many tissues of the
host. In healthy individuals, CMV can re-
activate intermittently with little conse-
quence; however, in immunocompro-
mised hosts, reactivation can lead to
end-organ disease (EOD).
In HIV infection, CMV EOD typically oc-
curs when CD4 cell counts decrease to
<50 cells/mm3. CMV retinitis, the most
common form of EOD in HIV infection, oc-
curs in 40% of individuals, with CD4 cell
counts <50 cells/mm3 (Pertel et al.,
1992). The incidence of CMV EOD hasdecreased substantially with the introduc-
tion of ART (Ledergerber et al., 1999; Pa-
lella et al., 1998). The increased incidence
of CMV disease in patients with AIDS
and restoration of protective immunity
to CMV with ART suggests that cellular
immunity is critical to the control of CMV
infection.
Cell-Mediated Immune Response
to CMV
The immune system utilizes tremendous
resources to control CMV. It is estimated
that 10% of the total memory CD4 and
CD8 T cell pool in CMV-seropositive
healthy donors is specific for CMV anti-
gens, with higher frequencies in certain
populations (Khan et al., 2004; Sester
et al., 2002; Sylwester et al., 2005). The
role of CD8 T cells in controlling CMV viral
replication has been well described in an-
imal models (Barry et al., 2007; Polic et al.,
1998; Reddehase et al., 1985). In humans,
seminal works by Riddell and Walter
showed that infusion of donor-derived
CMV-specific CD8 T cells not only
restored CMV-specific cellular immunity,
but also provided protection against
CMV clinical disease (Riddell et al.,
1992; Walter et al., 1995).Cell 155Although CD8 T cells have a clear role in
controlling CMV infection, CD4 T cells are
also critical to immune control. During pri-
mary CMV infection, there is a major
expansion of CMV-specific CD4 T cells,
and these responses appear before CD8
Tcell responses (Harari et al., 2004).Delays
in CD4 T cell response during primary
infection have been associatedwith symp-
tomatic infection and prolonged viral shed-
ding (Gamadia et al., 2003; Tu et al., 2004).
It has also been shown that recovery from
primary infection requires CMV-specific
CD4 T cell responses (Gamadia et al.,
2003).Whymight thisbe thecase?Koman-
duri et al. demonstrated that, althoughCD4
and CD8 T cell responses to CMV are sus-
tained over time, individuals maintaining
robustCD4Tcell responses aremore likely
to exhibit higher frequencies of CMV-spe-
cific CD8 T cells (Komanduri et al., 2001).
Thus, CMV-specific CD4 T cells are impor-
tant for maintaining and expanding the
CMV-specific CD8 T cell pool.
Apart fromproviding help toCD8Tcells,
CD4 T cells may control infection through
direct killing of virus-infected cells.
Casazza and colleagues demonstrated
that certain populations of CMV-specific, October 24, 2013 ª2013 Elsevier Inc. 509
Figure 2. Proposed Model for HIV-Associated Depletion of Pathogen-Specific CD4 T Cells
(Top) Mtb-specific CD4 T cell is activated upon binding to its cognate antigen on an HIV-infected antigen-
presenting cell (APC). T cell activation induces secretion of IL-2 and upregulation of CD25 (IL-2 receptor)
and CCR5 (HIV coreceptor). Binding of IL-2 to CD25 induces cellular proliferation (expression of prolif-
eration marker Ki67) and promotes viral replication, leading to productive HIV infection and cell death.
(Middle) Upon activation, CMV-specific CD4 T cells produce MIP-1b, which binds to its ligand, CCR5, an
HIV coreceptor, blocking HIV entry into the cell. Binding of MIP-1b to CCR5may also downregulate CCR5,
further impeding HIV entry. CMV-specific CD4 T cells express CD57, a marker to replicative senescence,
and do not enter the cell cycle, limiting HIV viral replication. Expression of TRIM and type I IFN may further
restrict HIV replication. These cells are less susceptible to productive HIV infection and targeted depletion.
(Bottom) Activation of cervical CD4 cells leads to increased expression of both CCR5 and the mucosal
homing receptor, integrin a4b7, which binds to HIV gp120. Coexpression of these receptors increases
susceptibility to HIV infection. These cells are also highly activated (express Ki67), promoting HIV repli-
cation and leading to productive infection and cell death.CD4 T cells contain granzyme A, gran-
zyme B, and perforin and that these cells
are capable of degranulating and killing
cells expressing their cognate antigen
(Casazza et al., 2006).
Impact of HIV on CMV
Immunobiology
Just as loss of Mtb-specific CD4 T cells
contributes to the increased risk of TB
disease in HIV-TB coinfection, loss of
CMV-specific T cells contributes to the
pathogenesis of CMVEOD in HIV-infected
individuals. Patients with active CMV
disease have diminished CMV-specific
T cell responses compared to individuals510 Cell 155, October 24, 2013 ª2013 Elseviwith immune recovery from CMV EOD
(Jacobson et al., 2001; Komanduri et al.,
1998). In a study evaluating the dynamics
of CMV-specific T cell responses, signifi-
cant reductions in CMV-specific IFNg-
producing CD4 T cells were seen in the
year prior to onset of CMV EOD (Bronke
et al., 2005). Coincident with the reduction
in CMV-specific CD4 T cells was a decline
in CMV-specific CD8 T cells producing
IFNg. This is not surprising, as CD4 T cell
help is required for maintaining and
expanding the CD8 T cell pool.
Unlike Mtb-specific CD4 T cell re-
sponses, the frequency of CMV-specificer Inc.CD4 T cell responses is generally main-
tained in chronic HIV infection and is
similar to that observed in CMV-seroposi-
tive, HIV-negative individuals (Komanduri
et al., 1998). In a recent study evaluating
CMV-specific T cell responses across
various HIV disease states, CMV-specific
CD4andCD8Tcell responseswerehigher
in chronic, untreated HIV infection than in
acute HIV infection (Naeger et al., 2010).
Why is it that, following HIV seroconver-
sion, Mtb-specific CD4 T cells are lost,
whereas CMV-specific CD4 T cells are
generally maintained? CMV-specific CD4
T cells produce MIP-1b and MIP-1a upon
stimulation and bind to CCR5, which also
serves as an HIV coreceptor. In addition,
CMV-specific CD4 T cells producing MIP-
1b have lower surface expression of
CCR5 and are less frequently infected
with HIV than CMV-specific CD4 T cells
that do not produce MIP-1b (Casazza
et al., 2009). We proposed that the auto-
crine production of b chemokines by
CMV-specificCD4 T cells blocksR5-tropic
HIV entry, either by direct competition or
downregulation of CCR5 surface expres-
sion. Recently, Hu and colleagues
extended thisobservation. Inanovel study,
they showed that neutralization of b che-
mokines led to enhanced HIV infection in
tetanus toxoid- and C. albicans-specific
CD4 T cells, whereas HIV infection of
CMV-specific CD4 T cells remained low,
suggesting postentry restriction of HIV by
CMV-specific CD4 T cells (Hu et al.,
2013). Microarray analysis revealed that a
broad array of innate antiviral genes was
activated in CMV-specific CD4 T cells,
includingseveral type I IFN responsegenes
and HIV/SIV restriction factors (TRIM22
and TRIM5). This implies that othermecha-
nisms may be involved in determining dif-
ferential susceptibilityofpathogen-specific
CD4 T cells to HIV infection.
Conclusions
The timing of opportunistic infections in
HIV infection is not always associated
with severity of CD4 T cell depletion, and
pathogen-specific differences in the
incidence of infection within CD4 strata
exist. Recent data suggest that functional
or phenotypic differences in pathogen-
specific CD4 T cells may influence the
timing of disease reactivation (Figure 2).
For example, Mtb-specific CD4 T cells
have high expression of CCR5 and
preferentially produce IL-2, leading to
increased susceptibility to HIV infection.
Cervical CD4 T cells also have increased
CCR5 expression but also express integ-
rin a4b7, increasing their susceptibility to
HIV infection. In contrast, CMV-specific
CD4 T cells preferentially produce b che-
mokines and express type I interferon
response genes and genes encoding
HIV restriction factors, all of which reduce
their susceptibility to productive HIV
infection and delay disease reactivation
until there is a profound loss of CD4
T cells. Although ART has reduced the
burden of many opportunistic infections,
pathogen-specific immunity is not always
fully restored, as the risk of infection from
certain opportunistic pathogens in im-
mune reconstituted HIV-positive individ-
uals continues to exceed that of the
general population.
The immunobiology of HIV and copath-
ogen infection remains quite complex,
and the mechanisms leading to differen-
tial susceptibility of pathogen-specific
CD4 T cells to HIV infection are only now
beginning to be understood. Powerful
technologies such as mulitparameter
flow cytometry and microarrays have
advanced our understanding, but novel
platforms allowing analysis at the single-
cell level may provide us with a better
appreciation of how these pathogen-spe-
cific differences are generated. As ART
is initiated even earlier in HIV infection, it
will be important to assess whether
earlier implementation improves path-
ogen-specific immunity. Although mech-
anistic studies of HIV and copathogen
infection are complex, a more thorough
understanding of this relationship will
better inform treatment strategies against
copathogens.
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